-continued

<210> SEQ ID NO 28
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<221> NAME/KEY: source
<223> OTHER INFORMATION: /note="Description of Artificial Sequence: Synthetic peptide"

<400> SEQUENCE: 28

Ser Gly Gly Gly Ser
1 5

<210> SEQ ID NO 29
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 29

Tyr Val Lys Met
1

What is claimed is:

1. A cell that is an immunostimulatory cell or precursor cell thereof, which cell recombinantly expresses (a) a chimeric antigen receptor (CAR), and (b) a dominant negative form of an inhibitor of a cell-mediated immune response of the immunostimulatory cell, wherein the CAR binds to a viral antigen.

2. A population of immunostimulatory cells or precursor cells thereof, which cell population comprises cells that recombinantly express (a) a chimeric antigen receptor (CAR), and (b) a dominant negative form of an inhibitor of a cell-mediated immune response of the immunostimulatory cell, wherein the CAR binds to a viral antigen.

3. The cell or cell population of claim **1** or **2**, wherein the immunostimulatory cell is a T cell.

4. The cell or cell population of any one of claims **1-3**, wherein the precursor cell is a hematopoietic stem or hematopoietic progenitor cell.

5. The cell or cell population of any one of claims **1-4**, wherein the immunostimulatory cell is a cytotoxic T lymphocyte (CTL).

6. The cell or cell population of claim **1** or **2**, wherein the cell is a T cell.

7. The cell or cell population of claim **1** or **2**, wherein the cell is a Natural Killer (NK) cell.

8. The cell or cell population of claim **1** or **2**, wherein the cell is a memory T cell.

9. The cell or cell population of claim **8**, wherein the memory T cell is a memory $CD8^+$ T cell.

10. A T cell that recognizes and is sensitized to a viral antigen, which T cell recombinantly expresses a dominant negative form of an inhibitor of a T cell-mediated immune response.

11. The T cell of claim **10** which is immunostimulatory.

12. The T cell of claim **10** or **11** which is $CD4^+$.

13. The T cell of claim **10** or **11** which is $CD8^+$.

14. A population of T cells, which cell population comprises T cells that recognize and are sensitized to a viral antigen and which recombinantly express a dominant negative form of an inhibitor of a T cell-mediated immune response.

15. The population of claim **14**, wherein the T cells are immunostimulatory.

16. The population of claim **14** or **15**, wherein the T cells are $CD4^+$.

17. The population of claim **14** or **15**, wherein the T cells are $CD8^+$.

18. The cell or cell population of any one of claims **1-17**, which is derived from a human.

19. The cell or cell population of claim **18**, wherein the viral antigen is of a virus that is a human pathogen.

20. The cell or cell population of any one of claims **1-19**, wherein the viral antigen can elicit an immune response in a human subject infected with the virus.

21. The cell or cell population of any one of claims **1-20**, wherein the viral antigen is selected from the group consisting of a human immunodeficiency virus (HIV) antigen, a hepatitis B virus (HBV) antigen, a hepatitis C virus (HCV) antigen, a herpes simplex virus (HSV) antigen, a varicella zoster virus (VZV) antigen, an adenovirus antigen, a cytomegalovirus (CMV) antigen, and an Epstein-Barr virus (EBV) antigen.

22. The cell or cell population of claim **21**, wherein the viral antigen is a HIV antigen selected from the group consisting of group-specific antigen (gag) protein, p55, p24, p18, envelope glycoprotein (env), gp160, gp120, gp41, reverse transcriptase (pol), p66, and p31.

23. The cell or cell population of claim **21**, wherein the viral antigen is a HBV antigen selected from the group consisting of HBV envelope protein S, HBV envelope protein M, HBV envelope protein L, and the S domain of HBV envelope protein S, M or L.

24. The cell or cell population of claim **21**, wherein the viral antigen is a HCV antigen selected from the group consisting of core protein, envelope protein E1, envelope protein E2, NS2, NS3, NS4, and NS5.

25. The cell or cell population of claim **21**, wherein the viral antigen is a HSV antigen selected from the group